MX2012013807A - Proteina de fusion que tiene actividad de factor vii. - Google Patents

Proteina de fusion que tiene actividad de factor vii.

Info

Publication number
MX2012013807A
MX2012013807A MX2012013807A MX2012013807A MX2012013807A MX 2012013807 A MX2012013807 A MX 2012013807A MX 2012013807 A MX2012013807 A MX 2012013807A MX 2012013807 A MX2012013807 A MX 2012013807A MX 2012013807 A MX2012013807 A MX 2012013807A
Authority
MX
Mexico
Prior art keywords
fusion protein
factor vii
fvii
vii activity
transferrin
Prior art date
Application number
MX2012013807A
Other languages
English (en)
Other versions
MX348567B (es
Inventor
Ho-Soon Lee
Bong-Yong Lee
In-Young Song
Hun-Taek Kim
Mahn-Hoon Park
Yun Jung Lim
Ji-Hye Lee
Seo Yeon Son
Min-Sun Kim
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of MX2012013807A publication Critical patent/MX2012013807A/es
Publication of MX348567B publication Critical patent/MX348567B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una proteína de fusión que comprende factor VII (FVII) y transferrina de conformidad con la presente invención, tiene una actividad específica mejorada de FVII en comparación con las proteínas de fusión de FVII existentes que comprenden otras parejas de fusión distintas a la transferrina, y por lo tanto se puede usar de manera efectiva en una terapia que usa FVII.
MX2012013807A 2010-06-04 2011-06-07 Proteina de fusion que tiene actividad de factor vii. MX348567B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100052719 2010-06-04
PCT/KR2011/004131 WO2011152694A2 (en) 2010-06-04 2011-06-07 Fusion protein having factor vii activity

Publications (2)

Publication Number Publication Date
MX2012013807A true MX2012013807A (es) 2012-12-17
MX348567B MX348567B (es) 2017-06-20

Family

ID=45067214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013807A MX348567B (es) 2010-06-04 2011-06-07 Proteina de fusion que tiene actividad de factor vii.

Country Status (13)

Country Link
US (2) US9644197B2 (es)
EP (1) EP2576625B1 (es)
JP (2) JP6143297B2 (es)
KR (1) KR101331101B1 (es)
CN (2) CN107188970A (es)
AU (1) AU2011262494B2 (es)
BR (1) BR112012030941A2 (es)
CA (1) CA2801223C (es)
ES (1) ES2676874T3 (es)
MX (1) MX348567B (es)
RU (1) RU2585231C2 (es)
WO (1) WO2011152694A2 (es)
ZA (1) ZA201300066B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
ES2873253T3 (es) * 2010-09-28 2021-11-03 Amryt Pharmaceuticals Inc Leptinas altamente solubles
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US20160060612A1 (en) 2013-02-25 2016-03-03 Sk Chemicals Co., Ltd. Method of Isolating and Purifying Fusion Protein Comprising Factor VII
KR102058864B1 (ko) * 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
MX2020001913A (es) 2017-08-18 2020-09-07 Neutrolis Inc Enzimas dnasa modificadas y uso en terapia.
JP7165884B2 (ja) 2017-10-30 2022-11-07 パナソニックＩｐマネジメント株式会社 棚札検出装置、棚札検出方法、及び、棚札検出プログラム
US10988746B2 (en) * 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
AU2019358915A1 (en) 2018-10-08 2021-05-20 Neutrolis, Inc. Engineering of DNASE enzymes for manufacturing and therapy
CN110229237A (zh) * 2019-06-24 2019-09-13 王跃驹 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1257295B1 (en) 2000-02-11 2009-04-15 Bayer HealthCare LLC Factor vii or viia-like molecules
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
MXPA04001804A (es) * 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
ES2355488T3 (es) 2001-08-30 2011-03-28 Biorexis Technology, Inc. Proteína de fusión de tranferrina modificadas.
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
WO2003092602A2 (en) 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
WO2004020454A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20070072271A1 (en) 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DK2004683T3 (en) * 2006-03-24 2016-08-22 Biogen Hemophilia Inc PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
BR112012013554A2 (pt) * 2009-12-08 2017-10-10 Koninl Philips Electronics Nv método de correção das medições de absorção do marcador para um paciente, programa de computador e sistema de correção
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质

Also Published As

Publication number Publication date
US20130236945A1 (en) 2013-09-12
BR112012030941A2 (pt) 2017-06-06
KR101331101B1 (ko) 2013-11-19
JP6143297B2 (ja) 2017-06-07
KR20110133454A (ko) 2011-12-12
JP2013529914A (ja) 2013-07-25
AU2011262494A1 (en) 2013-01-24
US10696960B2 (en) 2020-06-30
MX348567B (es) 2017-06-20
AU2011262494B2 (en) 2016-01-21
US9644197B2 (en) 2017-05-09
JP2017000144A (ja) 2017-01-05
ES2676874T3 (es) 2018-07-25
EP2576625B1 (en) 2018-04-25
WO2011152694A3 (en) 2012-04-19
EP2576625A2 (en) 2013-04-10
JP6422918B2 (ja) 2018-11-14
RU2012157301A (ru) 2014-07-20
US20160194622A1 (en) 2016-07-07
WO2011152694A8 (en) 2013-01-17
CA2801223C (en) 2019-12-03
RU2585231C2 (ru) 2016-05-27
CN107188970A (zh) 2017-09-22
AU2011262494A2 (en) 2013-08-01
ZA201300066B (en) 2014-03-26
WO2011152694A2 (en) 2011-12-08
CA2801223A1 (en) 2011-12-08
EP2576625A4 (en) 2013-11-06
CN103068854A (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
MX348567B (es) Proteina de fusion que tiene actividad de factor vii.
PH12017501417A1 (en) Anti-fap antibodies and methods of use
MX2015001083A (es) Polipeptidos de factor x modificados y usos de los mismos.
TN2014000438A1 (en) Anti-fcrn antibodies
MX357290B (es) Mejoramiento de la actividad de proteínas que requieren centros fe-s.
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
MX360741B (es) Constructos de polipéptidos y sus usos.
MX2013007168A (es) Anticuerpo anti-pcsk9 y metodos de uso.
IN2012DN05237A (es)
MX346518B (es) Metodos de desarrollo de variantes de terpeno sintasa.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
PT3434775T (pt) Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
PH12016500753B1 (en) Antibodies specific to fcrn
WO2012053823A3 (ko) 인자 ix 활성을 갖는 융합 단백질
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
PH12015501854A1 (en) Factor ix polypeptide formulations
WO2013006766A3 (en) Formulations that stabilize proteins
EP2496608A4 (en) FUSION PROTEIN SPECIFICALLY BINDING TO A CONSTANT REGION OF ANTIBODY, PREPARATION THEREFOR, AND METHOD OF ISOLATING ANTIBODY USING THE SAME
WO2013025846A3 (en) Transferrin-tumstatin fusion protein and methods for producing and using the same
WO2013059439A3 (en) Combination therapy comprising an mmp-14 binding protein
MX2016005572A (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
MX341733B (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.
MX2014001920A (es) Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
UA55856U (ru) Способ определения биологического эффекта магнитного поля
UA72607U (ru) Питательная среда для культивирования клеток, продуцирующих антиген вируса лейкоза крупного рогатого скота

Legal Events

Date Code Title Description
FG Grant or registration